RT Book, Section
A1 Buening, Natalie R.
A2 Attridge, Rebecca L.
A2 Miller, Monica L.
A2 Moote, Rebecca
A2 Ryan, Laurajo
SR Print(0)
ID 57296396
T1 Lab/Drug Interactions and Drugs of Abuse
T2 Internal Medicine: A Guide to Clinical Therapeutics
YR 2013
FD 2013
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-174580-2
LK accesspharmacy.mhmedical.com/content.aspx?aid=57296396
RD 2024/04/23
AB Table  Graphic  Jump  LocationTable  E-1  Drugs  of  Abuse:  Urine  Detection  Time*View  Table||Download  (.pdf)Table  E-1  Drugs  of  Abuse:  Urine  Detection  Time*(Mayo  Clin  Proc  2008;83:66;  Chyka  PA.  Substance  abuse  and  toxicological  tests.  Interpreting  Laboratory  Data  3rd  ed.  Bethesda,  MD:  American  Society  of  Health  System  Pharmacists,  2004)DrugTimeAmphetamines48h–2wkLong-term  use  =  2wkBarbiturates24h–4wkLong-acting  (phenobarbital)  =  4wkBenzodiazepines72h–4wkLong-acting  (diazepam)  =  4wkCocaine12–96hCannabinoids72h–  >4wkSingle  use  =  72h;  moderate  use  =  1wk;  daily  use  =  2wk;  long-term  use  ≥  4wkOpioids48h–1wkAssay  specific  for  morphine  with  varying  cross-reactivity  for  semisynthetic/synthetic  opioidsSustained  release  formulations  =  1wkPhencyclidine1wk–  >4wkLong  term  use  =  >4wk*Detection  times  affected  by  PK,  metabolites,  dose,  route,  time  of  last  ingestion,  body  mass,  urine  pH.